LUCID-MS: Patented new chemical entity (NCE)
Lucid-MS is a patented neuroprotective compound that has demonstrated in preclinical models to prevent and reverse myelin degradation, a cause for Multiple Sclerosis, as well as other neurodegenerative diseases and conditions.
Lucid-MS has shown excellent results in several animal models.
LUCID-MS: Disease Modifying Enabling Remyelination
A sampling of the novel qualities of Lucid-MS include:
- Excellent efficacy in various preclinical animal models
- Accelerates functional recovery of mouse models of Multiple Sclerosis, preserves myelin, and reduces zonal degradation
- Does not suppress immune system (non-immunomodulatory)
- Potential oral administration with easy dosing regimen
Quantum BioPharma has completed the dosing of healthy human volunteers for phase-1 clinical trials for Lucid-MS.
Today there is no cure for Multiple Sclerosis.
Quantum BioPharma ("QNTM") is trying to change this for millions of people.
Read more here from the company's not yet updated website.
-----
(Nasdaq: QNTM): 5 Potential Breakout Catalysts To Focus On Immediately
#1. A Minuscule Float Could Provide Strong Potential For Explosive Volatility.
According to the Yahoo Finance website, QNTM has a very small float.
In fact, the website reports this profile to have approximately 1.23Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could more positive company news midway through 2024 provide a near term spark?
-----
#2. Another Major Milestone Approaches As Upcoming Amazon Launch Nears.
Quantum BioPharma Provides Update on its In-vest-ment in Celly Nutrition Corp...
From the article:
John Duffy, CEO of Celly Nutrition, shares his excitement about this significant milestone: "...The successfully completed first production run of unbuzzd™ stick packs is one of the final steps before our August launch."
-----
#3. A "Pivotal Moment" On unbuzzd's™ Journey Ahead Of Expected Launch.
Quantum BioPharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)
TORONTO, ON / ACCESSWIRE / May 16, 2024 / Quantum BioPharma (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91), provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu"), its new packaging and logo of unbuzzd™ expected to launch this summer, an innovative beverage product that is scientifically formulated from a proprietary blend of vitamins, minerals and botanical extracts designed to support the body's natural processes for metabolizing alcohol and promoting alertness.
On May 16, 2024, Celly Nu and SIX+ONE unveil new packaging and logo for unbuzzd™ expected to launch this summer:
Toronto, Ontario, May 16, 2024 - Celly Nutrition Corp, makers of unbuzzd™, a pioneering beverage company for innovative, cutting-edge alcohol metabolizing technology for recreational use products, is thrilled to announce the launch of its newly designed packaging and logo, meticulously crafted in collaboration with the renowned branding agency, Six+One. This launch signifies a pivotal moment in unbuzzd's journey in preparation for the expected launch this summer.
...
John Duffy, CEO of Celly Nutrition, expressed his excitement about the new branding, stating, "At unbuzzd, we view branding as a crucial element in connecting with our consumers. It goes beyond visual identity; it's about making a meaningful impact. Our design encapsulates this philosophy by merging fun with sophistication, proving that serious products can be both enjoyable and engaging."
...
Read the full article here.
-----
#4. An Exclusive Option Agreement With The University Of Southern California Highlights Potential To Increase Target Markets.
Quantum BioPharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications
TORONTO, ON / ACCESSWIRE / June 13, 2024 / Quantum BioPharma (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91), ..., today announces that it entered into an exclusive option agreement with the University of Southern California (USC) to evaluate dietary supplement technology for commercialization. The option agreement, signed June 11, 2024, allows Quantum BioPharma to exclusively evaluate the novel technology for a 6-month term. At the end of this term, Quantum BioPharma will have the option to either extend it for an additional 6 months or to sign an exclusive license for the technology with USC. This novel technology is being evaluated for the potential to further increase the effectiveness of certain ingredients currently present in unbuzzd™. ...
"This partnership with Quantum BioPharma underscores USC's longstanding commitment to fostering innovation and translating scientific research into practical solutions that benefit society," said Dr. Erin Overstreet, executive director at the USC Stevens Center for Innovation. "We are excited to be working with Quantum BioPharma, leveraging their expertise in the biopharmaceutical industry, exploring the potential of this novel technology, and enhancing the portfolio of dietary supplement products. Together, we aim to bring forward new advancements that contribute to positive health and well-being for all."
...
Read the full article here.
-----
QNTM Recap - 4 Potential Breakout Catalysts To Know
#1. A Minuscule Float Could Provide Strong Potential For Explosive Volatility.
#2. Another Major Milestone Approaches As Upcoming Amazon Launch Nears.
#3. A "Pivotal Moment" On unbuzzd's™ Journey Ahead Of Expected Launch.
#4. An Exclusive Option Agreement With The University Of Southern California Highlights Potential To Increase Target Markets.
-----
Coverage is officially initiated on (Nasdaq: QNTM). Get it on your radar now!
Sincerely,
Kai Parker
StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
No comments:
Post a Comment